Medicare AdvantagePrior AuthMedium impact
MA08.073r, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Summary
This is a new Medicare Advantage policy (MA08.073r) effective April 1, 2025, establishing coverage guidelines for intravitreal injections of VEGF antagonists, VEGF biosimilars, and combination VEGF/Ang-2 inhibitors. The policy likely includes prior authorization requirements, medical necessity criteria, and coverage rules for these retinal disease treatments. Billing teams must review the full policy text to identify specific billing codes, authorization requirements, and any documentation mandates.
Action Required
By March 31, 2025: Billing and clinical teams must obtain and review the full policy text from the source URL. Identify: (1) specific HCPCS codes for covered VEGF antagonist injections (e.g., J2503, J2778, J2779, etc.), (2) prior authorization requirements and submission procedures, (3) medical necessity documentation requirements, and (4) any frequency or dosing limitations. Update billing system rules in EHR/PM software to enforce prior authorization workflows before April 1, 2025. Train clinical staff on documentation requirements for ophthalmology/retinal practices. Flag all intravitreal VEGF injection claims for prior auth review until workflows are confirmed. Failure to obtain authorization may result in claim denials.